We are live on ! Find out more
SAGE

Sage Therapeutics

Delisted

SAGE was delisted on the 30th of July, 2025.

143 hedge funds and large institutions have $927M invested in Sage Therapeutics in 2016 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 72 increasing their positions, 27 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 27

71% more call options, than puts

Call options by funds: $3.63M | Put options by funds: $2.12M

67% more funds holding in top 10

Funds holding in top 10: 610 (+4)

38% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 21

4% more funds holding

Funds holding: 137143 (+6)

32% less capital invested

Capital invested by funds: $1.37B → $927M (-$440M)

Holders
143
Holders Change
+6
Holders Change %
+4.38%
% of All Funds
3.81%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.27%
New
29
Increased
72
Reduced
27
Closed
21
Calls
$3.63M
Puts
$2.12M
Net Calls
+$1.51M
Net Calls Change
+$3.24M

SAGE Hedge Fund Activity: Q1 2016 in Review

143 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2016, worth a combined $927M — down 32% from $1.37B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new SAGE positions and 21 closed out — a net gain of 8 holders — while 72 added to existing stakes and 27 trimmed.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $26.4M. The largest seller was Lord, Abbett & Co, cutting an estimated $19.8M.

  • 143 institutional investors held Sage Therapeutics (SAGE) as of Q1 2016, up from 137 in Q4 2015.
  • Funds reported $927M of Sage Therapeutics stock for Q1 2016, down 32% quarter-over-quarter.
  • 29 funds opened new Sage Therapeutics positions in Q1 2016 and 21 closed out, a net change of +8 holders.
  • The largest Sage Therapeutics buyer in Q1 2016 was OppenheimerFunds, an estimated $26.4M added.
  • The largest Sage Therapeutics seller in Q1 2016 was Lord, Abbett & Co, an estimated $19.8M sold.

Based on aggregated 13F filings for Q1 2016.